Hidradenitis suppurativa–acne inversa (HS-AI) is a chronic inflammatory skin condition that involves the folliculopilosebaceous units. Histopathological studies have suggested that the occlusion of the follicular infundibulum and both innate and adaptive immunity play central roles.1,2 Limited data regarding the clinical aspects and prognosis of HS-AI are available. Patients affected by HS-AI may benefit from early dietary interventions aimed at the metabolic comorbidities that may predispose the patient to HS-AI, reducing weight as a secondary benefit. The rationalization of preventive and therapeutic approaches among centres may help to harmonize the clinical management of HS-AI internationally, with a lasting benefit to patients.
Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: Evidence from the national Italian registry / Bettoli, V.; Naldi, L.; Cazzaniga, S.; Zauli, S.; Atzori, L.; Borghi, A.; Capezzera, R.; Caproni, M.; Cardinali, C.; Devita, V.; Donini, M.; Fabbrocini, Gabriella; Gimma, A.; Pasquinucci, S.; Patrizi, A.; Pinna, A. L.; Raone, B.; Ricci, M.; Virgili, A.; Balestri, R.. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 174:1(2016), pp. 195-197. [10.1111/bjd.13864]
Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: Evidence from the national Italian registry
FABBROCINI, GABRIELLA;
2016
Abstract
Hidradenitis suppurativa–acne inversa (HS-AI) is a chronic inflammatory skin condition that involves the folliculopilosebaceous units. Histopathological studies have suggested that the occlusion of the follicular infundibulum and both innate and adaptive immunity play central roles.1,2 Limited data regarding the clinical aspects and prognosis of HS-AI are available. Patients affected by HS-AI may benefit from early dietary interventions aimed at the metabolic comorbidities that may predispose the patient to HS-AI, reducing weight as a secondary benefit. The rationalization of preventive and therapeutic approaches among centres may help to harmonize the clinical management of HS-AI internationally, with a lasting benefit to patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
bjd.13864.pdf
solo utenti autorizzati
Descrizione: articolo finale
Tipologia:
Versione Editoriale (PDF)
Licenza:
Accesso privato/ristretto
Dimensione
41.67 kB
Formato
Adobe PDF
|
41.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


